The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

Viking Therapeutics offers a speculative opportunity, driven by its promising obesity drug pipeline. Click here to read more ...

Novo Nordisk stock rose after good news from the FDA on Wegovy—it’s popular weight-loss drug which has the same active ...

NAION is a rare form of vision loss that’s been linked to semaglutide, the active ingredient in Wegovy and Ozempic.

According to NPR, doctors and patients alike have noted the drug has appeared to reduce some people's cravings for booze, ...

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from ...

Most people have likely heard about the new weight-loss and diabetes management drugs called Ozempic and Mounjaro, which are ...

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.